Skin cancer vaccine trial shows mRNA success

@bloombergbusiness

1.1M followers · usually 7.6K views a post

Views

44.0K

Likes

1.8K

Comments

76

Shares

294

SoundTikTok sound · original sound - bloombergbusiness

Promoted product

Moderna

Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.

6 videos5 creators

Why it worked

The video effectively combined a significant medical breakthrough with its immediate financial impact, creating a compelling narrative that appeals to both health and business interests. The clear explanation of the technology's potential and the positive market reaction likely drove engagement.

Summary

A late-stage clinical trial for a personalized mRNA cancer vaccine developed by Moderna and Merck has shown success in reducing melanoma recurrence and slowing its spread. This development has positively impacted the stock prices of both companies and suggests the potential of mRNA technology beyond COVID-19 vaccines.

Structure

1Introduction of the skin cancer vaccine trial
2Details of the vaccine's development and trial success
3Impact on Moderna and Merck stock prices

Original caption

A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Madison Muller explains. #medicine #cancer #health #business #news

More from @bloombergbusiness

Product placement

Moderna (company): develops and sells mRNA vaccines and therapeutics. It appears as a logo on a building and on a vaccine box. Removing it would not change what happens in the video. Merck (company): develops and sells pharmaceuticals, including immunotherapy drugs. It appears as a logo on a building. Removing it would not change what happens in the video. Keytruda (drug): an immunotherapy drug developed by Merck. It is mentioned as being combined with the vaccine. Removing it would change what happens in the video. Moderna COVID-19 Vaccine (product): a vaccine developed by Moderna. It appears on a box and a vial. Removing it would not change what happens in the video.

On-screen text

Skin cancer vaccine trial shows mRNA success A personalized mRNA cancer vaccine developed by Moderna and Merck, has achieved a major milestone in a late-stage clinical trial. Madison Muller Bloomberg News Combined with Merck's immunotherapy drug Keytruda, the custom shot helped reduce the recurrence of melanoma and slowed its spread to other parts of the body compared to Keytruda alone. Scientists analyzed each patient's tumor sample to create a tailored shot, targeting up to 34 unique mutations, training the immune system to hunt down remaining cancer cells. Wall Street reacted swiftly to the news. Moderna shares were up 100% when markets opened, the most since before the Covid pandemic, while Merck rose as much as 9.5% pandemic, while Merck rose as much as 9.5% The study provides the strongest evidence yet that mRNA technology can succeed beyond Covid-19 vaccines. The next test will be whether this success can translate to other types of cancers, as the companies hope.

Transcript

A personalized mRNA cancer vaccine developed by Moderna and Merck, has achieved a major milestone in a late-stage clinical trial. Madison Muller Bloomberg News Combined with Merck's immunotherapy drug Keytruda, the custom shot helped reduce the recurrence of melanoma and slowed its spread to other parts of the body compared to Keytruda alone. Scientists analyzed each patient's tumor sample to create a tailored shot, targeting up to 34 unique mutations, training the immune system to hunt down remaining cancer cells. Wall Street reacted swiftly to the news. Moderna shares were up 100% when markets opened, the most since before the Covid pandemic, while Merck rose as much as 9.5% pandemic, while Merck rose as much as 9.5% The study provides the strongest evidence yet that mRNA technology can succeed beyond Covid-19 vaccines. The next test will be whether this success can translate to other types of cancers, as the companies hope.